September 13, 2024

New Guidance Helps Clinicians Use Pemivibart to Protect Immunocompromised Patients From COVID-19

Key Points

Key points are not available for this paper at this time.

Abstract

This Medical News story discusses new guidelines for the use of pemivibart, a monoclonal antibody marketed as Pemgarda, as preexposure prophylaxis against COVID-19 in immunocompromised individuals.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Anna Bock (Fri,) studied this question.

synapsesocial.com/papers/68e58930b6db643587525453 https://doi.org/https://doi.org/10.1001/jama.2024.18589

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1COVID-19 Update: An EUA for Pemivibart (Pemgarda) for Pre-Exposure Prophylaxis2024 · 7 citations
2Real-world outcomes following pemivibart for COVID-19 pre-exposure prophylaxis in immunocompromised patients with hematologic malignancies2025
3660. Early Experience with Use of Pemivibart for the Pre-exposure Prophylaxis of Coronavirus Disease 20192026
4Pemivibart is less active against recent SARS-CoV-2 JN.1 sublineages2024 · 11 citations
5Immunobridging Analysis of Pemivibart for the Treatment of COVID-19 – A Therapeutic Gap for the Immune Compromised Remains2026

Ask AI

Helpful

Bookmark

View Full Paper